Clinical Effectiveness of Advanced Hybrid Closed-loop Systems for Achieving Time in Tight Range Among T1D Patients

Summary

Diabetes is a chronic disease with a relevant public health burden. Maintaining blood glucose levels as close to normal as possible is essential to avoid the associated microvascular and macrovascular complications. Therefore, the key to prevent and/or reduce the development of these chronic complications lies in an adequate and strict glycemic control. This study consist of a cross-sectional observational study among adult patients with type 1 diabetes (T1D). The main objective is to analyze the effect on time in tight range (TiTR, 70-140 mg/dL) of interstitial glucose between three different advanced hybrid closed-loop (AHCL) systems.

Eligibility

Inclusion Criteria:

* Patients with type 1 diabetes.
* Age greater than or equal to 18 years.
* Treated with advanced hybrid closed-loop systems (AHCL) for at least 3 months
* Actived continuous glucose monitoring data in the last 14 days.

Exclusion Criteria:

* Other types of diabetes.
* Receiving treatment with insulin regimens other than AHCL.
* Having received AHCL treatment for less than 3 months in a row prior to inclusion in the study with the same system.
* No data on use of the AHCL system during the previous 14 days.
* Severe or uncontrolled psychiatric disorder.
* Pregnancy or end of pregnancy less than 3 months ago or preparation for pregnancy.

Conditions2

Browse More Trials